The american society of transplant surgeons position statement supports use of caredx's allosure kidney for organ transplant surveillance

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the issuance of a new position statement by the american society of transplant surgeons (asts) supporting the use of caredx's allosure® kidney for organ transplant surveillance, and allosure heart and allomap® heart.
CDNA Ratings Summary
CDNA Quant Ranking